Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting
NCT02076529
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Colon Cancer
Interventions
DRUG:
Ramosetron 0.3mg
DRUG:
Ramosetron 0.45mg
DRUG:
Ramosetron 0.6mg
Sponsor
Chonnam National University Hospital